文献速递慢性肾脏病血液净化与透析

CKD患者钙化防御治疗的系统综述与荟萃分析

Treatment of Calciphylaxis in CKD: A Systematic Review and Meta-analysis.
PubMed 文献 · Kidney Int Rep · 2018-10-09

该研究系统检索并汇总了钙化防御在CKD患者中的5种常用治疗(硫代硫酸钠、甲状旁腺切除术、拟钙剂、高压氧、双膦酸盐)的病例报告、病例系列和队列研究。荟萃分析队列研究显示,上述治疗与未治疗相比,死亡率风险比均无显著差异,提示缺乏明确临床获益,需随机对照试验验证。

要点

  • 硫代硫酸钠、西那卡塞、高压氧、双膦酸盐及甲状旁腺切除术的死亡风险比均无显著差异。
  • 合并队列中50.3%患者接受硫代硫酸钠,28.7%行甲状旁腺切除术。
  • 现有证据不支持5种常用治疗对CKD钙化防御有显著临床获益。

核心结论

  • 系统综述发现5种最常用治疗对CKD钙化防御患者无显著临床获益,需随机对照试验验证疗效。

研究设计与样本

  • 系统综述纳入147篇文章,包括90例病例报告(90例患者)、20项病例系列(423例患者)和37项队列研究(343例患者)。
  • 对队列研究采用随机效应模型进行荟萃分析。

主要发现

  • 合并队列、病例系列和病例报告中,50.3%患者接受硫代硫酸钠,28.7%行甲状旁腺切除术,25.3%接受西那卡塞,15.3%接受高压氧,5.9%接受双膦酸盐。
  • 队列研究荟萃分析显示,硫代硫酸钠死亡风险比RR 0.89(95%CI 0.71-1.12),西那卡塞RR 1.04(95%CI 0.75-1.42),高压氧RR 0.89(95%CI 0.71-1.12),双膦酸盐RR 0.77(95%CI 0.44-1.32),甲状旁腺切除术RR 0.88(95%CI 0.69-1.13),均无显著差异。

临床怎么用

  • 临床医生应认识到现有证据未显示常用治疗有显著生存获益,治疗决策需个体化并充分告知不确定性。

局限性

  • 纳入研究以病例报告和病例系列为主,队列研究样本量有限,缺乏随机对照试验。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Calciphylaxis is a life-threatening complication of chronic kidney disease (CKD). To inform clinical practice, we performed a systematic review of case reports, case series, and cohort studies to synthesize the available treatment modalities and outcomes of calciphylaxis in patients with CKD. METHODS: Electronic databases were searched for studies that examined the uses of sodium thiosulfate, surgical parathyroidectomy, calcimimetics, hyperbaric oxygen therapy, and bisphosphonates for calciphylaxis in patients with CKD, including end-stage renal disease. For cohort studies, the results were synthesized quantitatively by performing random-effects model meta-analyses. RESULTS: A total of 147 articles met the inclusion criteria and were included in the systematic review. There were 90 case reports (90 patients), 20 case series (423 patients), and 37 cohort studies (343 patients). In the pooled cohorts, case series, and case reports, 50.3% of patients received sodium thiosulfate, 28.7% underwent surgical parathyroidectomy, 25.3% received cinacalcet, 15.3% underwent hyperbaric oxygen therapy, and 5.9% received bisphosphonates. For the subset of cohort studies, by meta-analysis, the pooled risk ratio for mortality was not significantly different among patients who received sodium thiosulfate (pooled risk ratio [RR] 0.89; 95% confidence interval [CI] 0.71-1.12), cinacalcet (pooled RR 1.04; 95% CI 0.75-1.42), hyperbaric oxygen therapy (pooled RR 0.89; 95% CI 0.71-1.12), and bisphosphonates (pooled RR 0.77; 95% CI 0.44-1.32), and those who underwent surgical parathyroidectomy (pooled RR 0.88; 95% CI 0.69-1.13). CONCLUSION: This systematic review found no significant clinical benefit of the 5 most frequently used treatment modalities for calciphylaxis in patients with CKD. Randomized controlled trials are needed to test the efficacy of these therapies.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Udomkarnjananun S, Kongnatthasate K, Praditpornsilpa K, et al. Treatment of Calciphylaxis in CKD: A Systematic Review and Meta-analysis. Kidney Int Rep. 2018. PMID: 30775620. doi:10.1016/j.ekir.2018.10.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。